Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses ddRNAi as Part of Infringement Settlement with Benitec

NEW YORK, August 11 (GenomeWeb News) - Benitec today said that it has settled a patent infringement case against Ambion, and that Ambion has taken a world-wide nonexclusive license to make and sell ddRNAi (DNA-directed RNAi) -based products as part of the settlement agreement.


Benitec said that the settlement "completely resolves all claims and counterclaims" asserted in a patent infringement dispute that began when the company filed suit against Ambion in March


Financial details of Ambion's licensing agreement were not disclosed.


Benitec has also accused two other firms -- Nucleonics and Genscript -- of infringing Benitec's ddRNAi patent, US Patent No. 6,573,099, entitled "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene." Benitec did not provide information on the status of these lawsuits.  


Benitec currently holds seven issued patents in five jurisdictions, including the US, UK, and Australia, covering RNAi in mammalian cells. The company said that an additional 65 RNAi-based patent applications are in "advanced stages of prosecution" in 14 other jurisdictions.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.